Search

Your search keyword '"Frankel, Stanley R."' showing total 232 results
Start Over Author "Frankel, Stanley R."
232 results on '"Frankel, Stanley R."'

2. Vorinostat

Author

Richon, Victoria M., Fantin, Valeria R., Ricker, Justin L., Frankel, Stanley R., and Schwab, Manfred, editor

Published
2017
Full Text
View/download PDF

4. Supplementary Figure 7 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

5. Data from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

6. Supplementary Figure 2 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 8 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

8. Supplementary Figure 1 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

9. Supplementary Figure 6 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 5 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Figure 3 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

12. Supplementary Figure 4 from Constitutive Activation of Signal Transducers and Activators of Transcription Predicts Vorinostat Resistance in Cutaneous T-Cell Lymphoma

Author

Fantin, Valeria R., primary, Loboda, Andrey, primary, Paweletz, Cloud P., primary, Hendrickson, Ronald C., primary, Pierce, Jacqueline W., primary, Roth, Jennifer A., primary, Li, Lixia, primary, Gooden, Frank, primary, Korenchuk, Susan, primary, Hou, Xiaoli S., primary, Harrington, Elizabeth A., primary, Randolph, Sophia, primary, Reilly, John F., primary, Ware, Christopher M., primary, Kadin, Marshall E., primary, Frankel, Stanley R., primary, and Richon, Victoria M., primary

Published
2023
Full Text
View/download PDF

13. Vorinostat

Author

Richon, Victoria M., Frankel, Stanley R., Ricker, Justin L., Fantin, Valeria R., and Schwab, Manfred, editor

Published
2011
Full Text
View/download PDF

15. Vorinostat

Author

Richon, Victoria M., Fantin, Valeria R., Ricker, Justin L., Frankel, Stanley R., and Schwab, Manfred, editor

Published
2009
Full Text
View/download PDF

22. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes

Author

Garcia-Manero, Guillermo, Yang, Hui, Bueso-Ramos, Carlos, Ferrajoli, Alessandra, Cortes, Jorge, Wierda, William G., Faderl, Stefan, Koller, Charles, Morris, Gail, Rosner, Gary, Loboda, Andrey, Fantin, Valeria R., Randolph, Sophia S., Hardwick, James S., Reilly, John F., Chen, Cong, Ricker, Justin L., Secrist, J. Paul, Richon, Victoria M., Frankel, Stanley R., and Kantarjian, Hagop M.

Published
2008
Full Text
View/download PDF

25. Vorinostat

Author

Richon, Victoria M., primary, Fantin, Valeria R., additional, Ricker, Justin L., additional, and Frankel, Stanley R., additional

Published
2012
Full Text
View/download PDF

26. Pretransplantation Consolidation Chemotherapy Decreases Leukemia Relapse after Autologous Blood and Bone Marrow Transplants for Acute Myelogenous Leukemia in First Remission

Author

Tallman, Martin S., Pérez, Waleska S., Lazarus, Hillard M., Gale, Robert Peter, Maziarz, Richard T., Rowe, Jacob M., Marks, David I., Cahn, Jean-Yves, Bashey, Asad, Bishop, Michael R., Christiansen, Neal, Frankel, Stanley R., García, Juan J., Ilhan, Osman, Laughlin, Mary J., Liesveld, Jane, Linker, Charles, Litzow, Mark R., Luger, Selina, McCarthy, Philip L., Milone, Gustavo A., Pavlovsky, Santiago, Phillips, Gordon L., Russell, James A., Saez, Ruben A., Schiller, Gary, Sierra, Jorge, Weiner, Roy S., Zander, Axel R., Zhang, Mei-Jie, Keating, Armand, Weisdorf, Daniel J., and Horowitz, Mary M.

Published
2006
Full Text
View/download PDF

27. Phase III Randomized Multicenter Study of a Humanized Anti-CD33 Monoclonal Antibody, Lintuzumab, in Combination With Chemotherapy, Versus Chemotherapy Alone in Patients With Refractory or First-Relapsed Acute Myeloid Leukemia

Author

Feldman, Eric J., Brandwein, Joseph, Stone, Richard, Kalaycio, Matt, Moore, Joseph, OʼConnor, Julie, Wedel, Nancy, Roboz, Gail J., Miller, Carole, Chopra, Raj, Jurcic, Joseph C., Brown, Randy, Ehmann, W Christopher, Schulman, Philip, Frankel, Stanley R., De Angelo, Daniel, and Scheinberg, David

Published
2005
Full Text
View/download PDF

30. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311

Author

Szatrowski, Ted P., Dodge, Richard K., Reynolds, Carol, Westbrook, Carol A., Frankel, Stanley R., Sklar, Jeffrey, Stewart, Carleton C., Hurd, David D., Kolitz, Jonathan E., Velez-Garcia, Enrique, Stone, Richard M., Bloomfield, Clara D., Schiffer, Charles A., and Larson, Richard A.

Subjects
Acute lymphocytic leukemia -- Drug therapy, Acute lymphocytic leukemia -- Patient outcomes, Ricin -- Dosage and administration, Ricin -- Evaluation, Ricin -- Health aspects, Cytarabine -- Dosage and administration, Cytarabine -- Evaluation, Health
Published
2003

32. A single, high dose of idarubicin combined with cytarabine as induction for adult patients with recurrent or refractory acute lymphoblastic leukemia

Author

Weiss, Mark A., Aliff, Timothy B., Tallman, Martin S., Frankel, Stanley R., Kalaycio, Matt E., Maslak, Peter G., Jurcic, Joseph G., Scheinberg, David A., and Roma, Todd E.

Subjects
Cancer -- Relapse, Acute lymphocytic leukemia -- Drug therapy, Cancer patients -- Health aspects, Idarubicin -- Health aspects, Cytarabine -- Health aspects, Health
Published
2002

33. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease inacute promyelocytic leukemia

Author

Miller, Wilson H., Jr., Kakizuka, Akira, Frankel, Stanley R., Warrel, Raymond P., Jr., DeBlasio, Anthony, Levine,Kristi, Evans, Ronald M., and Dmitrovsky, Ethan

Subjects
Acute leukemia, Promyelocytic -- Research, Tretinoin -- Research, Polymerase chain reaction -- Usage, Science and technology
Abstract

Acute promyelocytic leukemia is dramatically responsive to retinoic acid(RA) treatment that is characterized by the presence of fused PML and retinoic acid receptor alpha (RAR-alpha) genes on leukemic cell genomes. A reverse transcription-polymerase chain reaction (RT-PCR) method was developed to detectthese PML/RAR-alpha rearrangements. This method was found to be more sensitive and specific than conventional Northern analysis and cytogenetic detection methods. Also, all patients diagnosed with this method responded to RA therapy.These findings show that RT-PCR is a valuable tool in the diagnosis of APL and can be used to predict patient response to treatment.

Published
1992

34. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

Author

Marcucci, Guido, Byrd, John C., Dai, Guowei, Klisovic, Marko I., Kourlas, Peter J., Young, Donn C., Cataland, Spero R., Fisher, Diane B., Lucas, David, Chan, Kenneth K., Porcu, Pierluigi, Lin, Zhong-Pin, Farag, Sherif F., Frankel, Stanley R., Zwiebel, James A., Kraut, Eric H., Balcerzak, Stanley P., Bloomfield, Clara D., Grever, Michael R., and Caligiuri, Michael A.

Published
2003
Full Text
View/download PDF

36. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)

Author

Warrell, Raymond P., Jr., Frankel, Stanley R., Miller, Wilson H., Jr., Scheinberg, David A., Itri, Loretta M., Hittelman, Walter N., Vyas, Rohini, Andreeff, Michael, Tafuri, Agostino, Jakubowski, Ann, Gabrilove, Janice, Gordon, Michael S., and Dmitrovsky, Ethan

Subjects
Cell differentiation -- Physiological aspects, Tretinoin -- Health aspects, Acute leukemia, Promyelocytic -- Care and treatment, Cancer -- Differentiation therapy
Abstract

During the normal course of embryonic and fetal development, many cells must replicate themselves again and again. At some point, however, some cells must stop replicating and begin to take on their proper mature characteristics. This process is called differentiation. There are many reasons to draw parallels between cancer cells and the replicating cells which have not yet undergone differentiation. This is especially true in the case of acute promyelocytic leukemia, which constitutes about 15 percent of all adult acute nonlymphoblastic leukemias. This particular leukemia has been associated with a genetic defect that seems to affect the receptor for retinoic acid, a molecule closely related to vitamin A. Retinoic acid and its receptor are believed to play a key role in the regulation of normal differentiation. A study was undertaken to determine if this relationship between differentiation and acute promyelocytic leukemia could be used to therapeutic advantage. Eleven leukemia patients were treated with tretinoin, a variety of retinoic acid with a molecular bond arrangement referred to as "all-trans". Nine of these 11 patients entered complete remission. The analysis of blood samples revealed that the remissions were associated with the maturation of the clones of cells responsible for the leukemia. That is, the tretinoin did not kill the leukemic cells, but rather stimulated them to change from cancerous cells into normal mature cells which do not divide. At the time of the publication of the study results, the remissions had lasted from 1.5 months to more than six months. The tretinoin treatment was well tolerated, with the most common side effect being mild headache. However, two patients did experience an elevation in pressure of their cerebrospinal fluid. Other side effects included skin rash and nasal congestion. Tretinoin appears to be a safe and highly effective agent in the treatment of acute promyelocytic leukemia. (Consumer Summary produced by Reliance Medical Information, Inc.)

Published
1991

43. Target discovery for T cell therapy: next steps to advance Immunotherapies

Author

Bot, Adrian, primary, Brewer, Joanna E, additional, Eshhar, Zelig, additional, Frankel, Stanley R, additional, Hickman, Emma, additional, Jungbluth, Achim A, additional, Morgan, Richard, additional, Peretz, Yoav, additional, Radvanyi, Laszlo, additional, Ramos, Carlos A, additional, Robbins, Paul F, additional, and Wucherpfennig, Kai W, additional

Published
2015
Full Text
View/download PDF

44. Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Author

Krupka, Christina, primary, Brauneck, Franziska, additional, Lichtenegger, Felix S, additional, Kufer, Peter, additional, Kischel, Roman, additional, Zugmaier, Gerhard, additional, Köhnke, Thomas, additional, Altmann, Torben, additional, Schneider, Stephanie, additional, Fiegl, Michael, additional, Spiekermann, Karsten, additional, Sinclair, Angus M, additional, Newhall, Kathryn J, additional, Frankel, Stanley R, additional, Baeuerle, Patrick, additional, Hiddemann, Wolfgang, additional, Riethmüller, Gert, additional, and Subklewe, Marion, additional

Published
2014
Full Text
View/download PDF

46. PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Author

Krupka, Christina, primary, Kufer, Peter, additional, Kischel, Roman, additional, Zugmaier, Gerhard, additional, Köhnke, Thomas, additional, Lichtenegger, Felix S, additional, Schnorfeil, Frauke M, additional, Altmann, Torben, additional, Schneider, Stephanie, additional, Fiegl, Michael, additional, Spiekermann, Karsten, additional, Sinclair, Angus M, additional, Newhall, Kathryn J, additional, Frankel, Stanley R, additional, Baeuerle, Patrick, additional, Hiddemann, Wolfgang, additional, Riethmüller, Gert, additional, and Subklewe, Marion, additional

Published
2014
Full Text
View/download PDF

48. Vorinostat

Author

Richon, Victoria M., primary, Fantin, Valeria R., additional, Ricker, Justin L., additional, and Frankel, Stanley R., additional

Full Text
View/download PDF

50. Reversible Tacrolimus-induced Neurotoxicity Isolated to the Brain Stem

Author

Oliverio, Patrick J., Restrepo, Lucas, Mitchell, Sandra A., Tornatore, Carlo S., and Frankel, Stanley R.

Subjects
Adult, Remission, Spontaneous, Brain, Magnetic Resonance Imaging, eye diseases, Tacrolimus, surgical procedures, operative, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Humans, Female, Neurotoxicity Syndromes, Immunosuppressive Agents, Bone Marrow Transplantation, Brain Stem, Follow-Up Studies
Abstract

Summary: Diplopia, nystagmus, visual hallucinations, and internuclear ophthalmoplegia developed in a 30-year-old woman 84 days after she received a matched, unrelated bone marrow transplant for chronic myeloid leukemia. A regimen of tacrolimus had been administered since the transplantation was performed. MR imaging revealed bilaterally symmetric regions of signal abnormality with abnormal contrast enhancement in the brain stem. No supratentorial abnormality was present. Tacrolimus therapy was discontinued, and the symptoms resolved. MR imaging that was performed 10 days after tacrolimus was discontinued showed resolution of the abnormalities.

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results